Fractyl Health, Inc. stocks have been trading down by -52.95 percent amid heightened scrutiny of its metabolic gene therapy prospects.
Click Here for a Millionaire's POV on Trading GUTS
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For GUTS Traders
- Shares of Fractyl Health (NASDAQ:GUTS) collapsed about 68%–75% in two days after weak six‑month REMAIN‑1 Midpoint Cohort data and disclosure of an outlier trial site.
- A sweeping securities class action targets GUTS traders who bought shares between 2025/01/13 and 2026/01/29, focusing on alleged misstatements around trial design, data integrity, and risk disclosure.
- The company is accused of using allegedly inflated interim Revita data and undisclosed site‑level issues to time two 2025 equity offerings that raised roughly $76.7M.
- Following the data disappointment, GUTS was downgraded by Morgan Stanley, which also slashed peak sales expectations for Revita’s weight‑maintenance profile.
- Multiple law firms now promote or file class actions over Revita and REMAIN‑1, creating a persistent legal and reputational cloud over Fractyl Health and GUTS trading.
Live Update At 07:46:46 EDT: On Friday, October 16, 2026 Fractyl Health, Inc. stock [NASDAQ: GUTS] is trending down by -52.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Fractyl Health, the company behind GUTS, now trades like a damaged story stock. The recent chart shows exactly that. In late September, GUTS changed hands around $0.55. By early October, after the reverse split and crash, adjusted prices briefly printed near $0.40 before grinding back into the low‑$4 range.
For traders, that is a textbook volatility spike followed by a dead‑cat style bounce. Daily candles for GUTS between 2026/10/02 and 2026/10/15 show wide ranges and shaky closes, signaling tug‑of‑war between bargain hunters and sellers hitting every pop.
More Breaking News
- Diamondback Energy Stock Climbs as Street Hikes Price Targets
- TRGP Jumps As Targa Resources Price Targets Surge Before Q3
- SPCH Slides Lower As Short-Term Momentum Weakens
- FMX Rises As FEMSA Locks In Cheap Swiss Debt
Under the hood, Fractyl Health is still a pre‑revenue biotech burning cash. In Q2 2026, the company posted a net loss of about $25.5M and negative free cash flow near $15.9M, while research and development hit $13.8M. GUTS has roughly $47.1M in cash and a solid current ratio around 3.2, but book value is negative and returns on assets are deeply in the red. That mix – big losses, heavy R&D, and a shrinking cash runway – means future financing remains a real overhang for GUTS traders.
Why Traders Are Watching GUTS After The Collapse
GUTS is in the spotlight because the core bull thesis was smashed in public. Fractyl Health built excitement around its Revita DMR System and the REMAIN‑1 trial, pitching durable weight maintenance after GLP‑1 therapy. Then the six‑month Midpoint Cohort data landed. Instead of stable weight, results showed meaningful regain, and the company also disclosed operational problems at a key trial site labeled an “outlier.”
Once that hit, GUTS did not just drift lower; it was repriced. Reports describe a 68%–75% collapse in roughly two days, followed by a Morgan Stanley downgrade and a cut in Revita peak sales expectations. For active traders, that is the moment the market decided Revita might not be the blockbuster earlier three‑month data suggested.
The legal aftermath is driving the next chapter. Multiple securities class actions now accuse Fractyl Health of overstating Revita’s efficacy, downplaying trial‑site issues in REMAIN‑1, and then using allegedly inflated interim data to push through two equity offerings in August and September 2025 that raised about $76.7M. The suit covers anyone who traded GUTS between 2025/01/13 and 2026/01/29, tying the legal claims directly to that hype‑to‑crash window.
For short‑term traders, this cocktail – clinical doubt, financing questions, and headline‑driven lawsuits – usually means big intraday swings. The 5‑minute tape already shows GUTS whipping from the mid‑$4s to below $2 and back toward $2 in a single premarket stretch, a clear signal that day traders are crowding into the name.
Conclusion
Right now, GUTS sits where many broken biotech stories end up: high risk, heavy emotion, and plenty of rumors. Fractyl Health faces accusations that it overstated Revita’s clinical prospects, failed to flag operational problems at a key REMAIN‑1 site, and raised tens of millions of dollars off interim data that now looks far less impressive. On top of that, a class period running from 2025/01/13 to 2026/01/29 and an October 20, 2026 lead‑plaintiff deadline ensure the legal saga will keep GUTS in the news.
For traders, that means one thing – volatility. Legal updates, analyst notes, or any new Revita data can spark sharp spikes or flushes. The balance sheet shows GUTS still has cash, but the burn rate and negative equity highlight why the market focuses on future capital raises and dilution risk. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” That mindset is especially relevant with a ticker like GUTS, where the story can change overnight and risk management has to come before the chase for home‑run trades.
This is exactly the kind of setup Tim Sykes talks about when he says, “Volatile story stocks can be gold mines for prepared traders, but only if you respect the risks, cut losses quickly, and never fall in love with the hype.” With GUTS, disciplined trade plans, tight risk controls, and careful attention to every new headline are not optional – they are the whole strategy. This analysis is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.